The stock of AtriCure Inc. (NASDAQ:ATRC) is a huge mover today! About 212,370 shares traded hands. AtriCure Inc. (NASDAQ:ATRC) has risen 3.15% since March 8, 2016 and is uptrending. It has underperformed by 6.17% the S&P500.
The move comes after 5 months negative chart setup for the $544.79 million company. It was reported on Oct, 11 by Barchart.com. We have $15.55 PT which if reached, will make NASDAQ:ATRC worth $32.69 million less.
Analysts await AtriCure Inc. (NASDAQ:ATRC) to report earnings on October, 25. They expect $-0.28 earnings per share, down 27.27% or $0.06 from last year’s $-0.22 per share. After $-0.26 actual earnings per share reported by AtriCure Inc. for the previous quarter, Wall Street now forecasts 7.69% negative EPS growth.
AtriCure Inc. (NASDAQ:ATRC) Ratings Coverage
Out of 7 analysts covering Atricure Inc. (NASDAQ:ATRC), 6 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 86% are positive. Atricure Inc. has been the topic of 13 analyst reports since July 30, 2015 according to StockzIntelligence Inc. On Tuesday, July 28 the stock rating was maintained by Dougherty & Company with “Buy”. BTIG Research initiated the shares of ATRC in a report on Friday, August 7 with “Buy” rating. The company was maintained on Tuesday, October 6 by Needham. UBS initiated AtriCure Inc. (NASDAQ:ATRC) on Tuesday, September 22 with “Sell” rating. The company was maintained on Wednesday, July 29 by Needham. The firm earned “Sell” rating on Friday, August 5 by UBS. The stock has “Buy” rating given by Canaccord Genuity on Tuesday, October 6. Northland Capital initiated it with “Outperform” rating and $24 target price in Tuesday, March 29 report. Needham maintained the shares of ATRC in a report on Tuesday, August 4 with “Buy” rating. On Friday, August 5 the stock rating was maintained by Stifel Nicolaus with “Buy”.
According to Zacks Investment Research, “AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure, Inc. bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, a quivering of the upper chambers of the heart.”
Insitutional Activity: The institutional sentiment decreased to 0.96 in 2016 Q2. Its down 0.19, from 1.15 in 2016Q1. The ratio worsened, as 15 funds sold all AtriCure Inc. shares owned while 31 reduced positions. 5 funds bought stakes while 39 increased positions. They now own 24.21 million shares or 10.01% less from 26.90 million shares in 2016Q1.
Blackrock Invest Mngmt Lc owns 122,066 shares or 0% of their US portfolio. Voya Inv Management Ltd Liability Company last reported 15,908 shares in the company. Moreover, Tarbox Group has 0.02% invested in AtriCure Inc. (NASDAQ:ATRC) for 2,052 shares. Rockefeller Financial owns 16,480 shares or 0% of their US portfolio. Great West Life Assurance Can has 2,154 shares for 0% of their US portfolio. The Florida-based Ladenburg Thalmann Fin Services Inc has invested 0% in AtriCure Inc. (NASDAQ:ATRC). Us State Bank De has invested 0% of its portfolio in AtriCure Inc. (NASDAQ:ATRC). California State Teachers Retirement System last reported 0% of its portfolio in the stock. Massachusetts Services Com Ma owns 416,353 shares or 0% of their US portfolio. California Pub Employees Retirement Sys has 0% invested in the company for 41,200 shares. Millennium Mgmt Limited Liability Company holds 0.03% of its portfolio in AtriCure Inc. (NASDAQ:ATRC) for 903,930 shares. Victory Capital Management Inc last reported 52,330 shares in the company. Blackrock Advsr Ltd Liability reported 14,654 shares or 0% of all its holdings. Ubs Asset Mgmt Americas Inc has 0% invested in the company for 12,100 shares. Macquarie Group Limited reported 92,300 shares or 0% of all its holdings.
Insider Transactions: Since August 16, 2016, the stock had 0 buys, and 2 sales for $171,580 net activity. Another trade for 6,000 shares valued at $95,580 was sold by Krell Elizabeth D.
Another recent and important AtriCure Inc. (NASDAQ:ATRC) news was published by Businesswire.com which published an article titled: “AtriCure Announces Approval for the AtriClip in Japan” on January 19, 2016.
ATRC Company Profile
AtriCure, Inc., incorporated on October 31, 2000, is a medical device firm providing atrial fibrillation (Afib) solutions. The Company’s segment develops, makes, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Firm has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. The Firm offers various minimally invasive ablation devices and access tools to facilitate less invasive cardiac and thoracic surgery. The Company’s cryoICE cryosurgery product line offers various cryoablation devices. The Company’s AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart’s left atrial appendage (LAA). The Company’s products are utilized by cardiothoracic surgeons during both open-heart and minimally invasive procedures, either on a concomitant or sole-therapy basis. The Company’s Isolator Synergy System, which includes its Isolator Synergy clamps, radio frequency (RF) generator and related switchbox, provides treatment for persistent and long-standing persistent Afib concomitant to other open-heart surgical procedures, such as coronary artery bypass grafting and/or valve replacement or repair. The Firm has two primary product lines for cardiac tissue ablation, which include Radio Frequency Ablation Devices and cryoICE Cryoablation System, and a product line for left atrial appendage exclusion.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.